Pacemaker resynchronisation in the treatment of severe heart failure

摘要: Patients with heart failure (HF) are at increased risk for hospitalisations, arrhythmias, and mortality. Despite convincing evidence that combined diuretics, angiotensin-converting enzyme inhibitors (ACEI), β-blockers, aldosterone antagonists (i.e. optimal drug therapy) can reduce hospitalisations mortality in patients HF, such life-prolonging therapy continues to be underutilised [1]. More recently, devices the management of including implantable cardioverter-defibrillators (ICDs) pacemaker cardiac resynchronisation (CRT)1 have been shown result substantial reduction [2]–[5]. Thus, CRT is yet another may benefit selected severe failure.